Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Common Stock Issued

Cash raised by issuing new shares.

Upstream Bio, Inc.NASDAQ: UPB

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued turns positive

Q1 FY2026 common stock issued was $598K, compared with -$34K a year earlier. Trailing-twelve-month common stock issued was $3.07M. Over 3 fiscal years it compounded at -37.4% a year.

Context

  • Common stock issued amounted to 85.5% of revenue in FY2025, down 11421.8 pp from a year earlier.
  • Common stock issued increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock issued holds near $598K or moves back toward the trailing-twelve-month quarterly average of $768.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$598K-45.8% QoQ
Last fiscal yearDec 2025
$2.44M-99.1% YoY
LTMMar 2026
$3.07M-98.9% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1858.8%——
1 year-99.1%——
3-year CAGR-37.4%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

USD · from the cash flow

Latest · FY2025
2.44M USD
Year-over-year change
-99.1%
3-year CAGR
-37.4%

Common Stock Issued vs competitors

How UPB compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -98.9% is the 8th highest of 9, against a peer median of +74.7%.
  • Common stock issued amounts to 92.5% of revenue for UPB, versus a peer median of 462.6%.
UPB Competitors
Common Stock Issued for UPB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$757.86M USD+235.4%+94.3%837.5%
WVEWave Life Sciences Ltd.LTM Mar 2026$486.47M USD+117.8%+110.5%677.6%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$463.47M USD+111.7%-82.2%4478.0%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$319.3M USD-23.8%+37.1%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$277.53M USD+7110.3%-15.6%—
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$163.72M USD+37.7%-38.5%247.7%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$20.66M USD—-57.8%9.5%
PHVSPharvaris N.V.LTM Sep 2026€6.56M EUR-96.2%+161.4%—
UPBUpstream Bio, Inc.LTM Mar 2026$3.07M USD-98.9%-37.4%92.5%
NVAXNovavax, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
Peer median (excluding UPB) —+74.7%+10.8%462.6%

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Depreciation & Amortization7K60K89K(1.31M)
Deferred Income Tax0000
Stock-Based Compensation1.28M3.43M6M10.33M
Change in Working Capital3.41M(4.31M)1.87M589K
Accounts Receivables(412K)314K(515K)(55K)
Inventory0000
Accounts Payables462K1.28M2.02M(1.28M)
Other Working Capital3.36M(5.9M)371K1.93M
Other Non-Cash Items149K(16.57M)(4.33M)561K
Operating Cash Flow(19.02M)(37.93M)(59.17M)(133.28M)
Capital Expenditures(82K)(144K)(511K)(165K)
Acquisitions (Net)0000
Purchases of Investments0(128.99M)(290.61M)(385.88M)
Sales of Investments046.29M231.64M292.56M
Other Investing Activities0000
Investing Cash Flow(82K)(82.84M)(59.49M)(93.48M)
Debt Repayment0000
Common Stock Issued9.96M129.55M272.72M2.44M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(37K)118K(3.74M)0
Financing Cash Flow9.96M129.55M418.91M2.44M
Effect of Forex Changes0000
Net Change in Cash(9.14M)8.78M300.25M(224.31M)
Free Cash Flow(19.1M)(38.07M)(59.68M)(133.28M)

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.